Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good post.
And you know that what they've tested. It's probably not even close to being accurate. They're probably up to almost a million cases a day.
They should be shipping that drug as fast as they can make it to India.
And this is just the beginning over there as they don't have no way of containment.
I've been over there, but it's been quite a few years, and it's crazy full of people everywhere.
I took a cab and they were actually pushing people out the way to get down the street. And sometimes it wasn't even a tap, more like a hit.
They don't get some help soon we'll probably see deaths exceeding $10,000 a day and perhaps up the $25,000 a day.
Let's see if the world has the resolve to get on this pandemic and how quickly they expedite it.
Good job....
It would seem more capacity is coming online soon. Perhaps a beat on EPS numbers and revenue.
Put that together with the 100 million dollar buyback (just kidding) and we're over 30 bucks a share.
Great play but I'd have to stay away from that margin. The stock is much too volatile. I've gotten caught a couple times dropped 50k.
Good luck to you buddy.
I can't wait to 70 is the new 50.
We have to give it some time, I am getting impatient too. It's silly because we've had such a great run over the past 4 to 6 months months.
I know we're going to do well and a lot of it should unfold over the next few months. The CC is going to be critical with information. Very much looking forward to it.
April 22nd was a good day, almost a million.
I probably did.
Sorry about giving you a hard time.
I just haven't found a better place to park my money.
As far as all this institutional money coming in, all needing exposure to the cdmo space, at the same time it's amazing.
That idea is both convenient and irrational.
You're either in denial, orange desperate need of a physician.
No offense.
CDMO is going higher, perhaps against your wishes.
Cdmo
If that was a nickel, I'd hate to get a dime.
You do realize that people can't digest that much truth in one post.
Break it up to 4 post next time.
It's near perfect except for some minor imperfections (the imperfections could be mine and not yours).
The risk you mentioned of having just one main customer is considered an asset when determining value on a cdmo. Recent aquasistions favors cdmo's with fewer customers as a move to another provider is higher unlikely or nearly impossible.
Margins will most certainly rise to 40% or better.
The pandemic has most certainly changed the dynamics of the CDMO space. Domistic providers are abosute for national security. Value added for Avid...
They just didn't get to you.
A half million dollars worth was bought at $22.10.
It's much too reasonable for me. I'm in with a cost basis of 3.51. No way in the world would I keep this position if I didn't think it was going much higher than 30 in the next 18 months.
You care to explain why all the fund managers are still buying even though we're above our one year price Target.
Before the pandemic the M&A valuation on a sale was between 17 and 21 times EBIDA.
I guess you have a $60 price Target too but you arrive at yours by doing a three to one reverse split.
Endo , do you have a valuation and a price target that you're comfortable with for avid?
21,750 at 22.10....
That was the biggest block I've seen.
Treatment Order (CTO)
By
WILL KENTON
Updated Apr 8, 2019
What Does Confidential Treatment Order Mean?
A confidential treatment order (CTO) is an order that provides confidential treatment for certain documents and information that a company would otherwise have to file with the Securities and Exchange Commission (SEC). A confidential treatment order is issued by the SEC and may only be in effect for a certain period of time. If a company wishes to omit certain information from their required filings they can complete a confidential treatment order request, which is reviewed by the SEC. The request must contain the information the company is looking to withhold and the time period the company is looking to withhold the information. This includes providing a date upon which the CTO would expire. Only certain types of information can be held confidential and the requesting company must provide evidence that disclosure of the information would provide it competitive harm.
Understanding Confidential Treatment Order (CTO)
Companies would typically seek a confidential treatment order (CTO) to keep information secret that would otherwise put it at a competitive disadvantage if revealed. A company would seek the confidential treatment order by filing a formal request, a confidential treatment request (CTR), with the Securities and Exchange Commission (SEC).
Example of a Confidential Treatment Order
For example, a company may apply for a confidential treatment order by completing a confidential treatment request to keep information regarding a pricing arrangement made with a potential acquisition target secret. This request could be made on the basis that the company's competitors may use this information to go after the target with a more competitive price. Other common items kept confidential include milestone payments and other technical specifications.
Ad
Sec
material fact" means a material fact for the purposes of Applicable Securities Laws or any of them, or where undefined under the Applicable Securities Laws of an Offering Jurisdiction means a fact that would reasonably be expected to have a significant effect on the market price or value of any securities of the Company;
I'm sure glad I picked up some at 15. Should be going to 30 or 40 with any good news.
CDMO should break all time highs this week considering the new approved cancer drug from ADCT which CDMO is manufacturing.
There's no way we should be just sitting around trading 100,000 shares. They've got five days to put out an 8K unless they're working with people trying to collect shares. That's the rule.
I'm sure that ADCT will increase our revenue by more than 5%. That requires an 8K and the pr. If I remember correctly they have 5 days to do it although it might be three I can't remember.
ADC Therapeutics up 9% as Cowen calls Zynlonta 'best in class' for B-cell lymphoma
Protector.
I appreciate what you're saying but I've worked with market makers(thinkequity) and a few others. I've also written a lot of PR's for companies on the NASDAQ. I was a consultant to several companies. One which we took from 3 million market cap and sold almost 300 million five years later. That was quite a few years ago but I know how it works.
It is a cornucopia good and great news. I believe we're at the point of critical mass. Looks like manipulation won't get many shares at this point. If anyone wants to come in and get a decent position, you'll have to pay up, and that should drive the stock higher, breaking the stock into 52-week highs. Momentum traders will help propel us to new levels.
ENHANZE® Drives 86% Year-over-year and 34% Sequential Growth in Royalties in the Fourth Quarter -
- 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue -
- 2021 Royalties Projected to Double versus 2020 Royalties -
- 2021 EPS Guidance of $1.40 to $1.55 Representing 54%-70% Growth over 2020 EPS -
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020
ENHANZE® technology. Building on our portfolio of 5 commercialized partner products, we project the expansion of our development pipeline, including 4 products being evaluated in 7 phase 3 studies utilizing our ENHANZE® technology. We believe this advancing pipeline of products utilizing our ENHANZE® technology is setting the potential for multiple waves of future product launches that will deliver long-term growth in revenues, profitability and cash flow."
Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
Let's hear some predictions on Monday..
My guess it's a close above 22.
But you know sometimes it takes a few days for fund managers to get up to speed so it might be Wednesday or Thursday or maybe even next week before they catch on. The buyers last week already got the news.
Don't do it next time because we don't have another 25-30 years to wait.
A lot of the old staff did a reverse merger into cpmv. I ended up with a few thousand shares and soon as it gets straight I'm going to buy some because they have a habit of running things up to begin with. Make sure you sell the run.
ADCT 8K equivalent issued yesterday.
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2021.
Commission File Number: 001-39071
ADC Therapeutics SA
(Exact name of registrant as specified in its charter)
Biopôle
Route de la Corniche 3B
1066 Epalinges
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
?
Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ?
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ?
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ADC Therapeutics SADate: April 23, 2021 By:/s/ Michael Forer Name:Michael Forer Title:Executive Vice President & General Counsel
EXHIBIT INDEX
Exhibit No.Description99.1Press release dated April 23, 2021
Next CC should be a New Years Eve party......
I'm thinking 25 by then.....
Good find......
Who's up a PR and an 8k....
An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission (SEC).
I think 500 million could do it as long as we're still growing at this insane rate.
Almost looks like a pandemic pure play.
We're going to be getting vaccines for a while, perhaps indefinitely.
This closing last 5 minutes should be interesting......
It sure is on fire....
.
Cambrex Completes Acquisition of Halo Pharma
September 12, 2018
East Rutherford, NJ – Sept 12, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced it has completed the acquisition of Halo Pharma (Halo), a leading dosage form Contract Development and Manufacturing Organization (CDMO) located in Whippany, New Jersey and Mirabel, Québec, Canada, for approximately $425 million.
This completes the transaction initially announced on July 23, 2018. The addition of the facilities adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
The newly acquired Cambrex Whippany and Cambrex Mirabel provide formulation development and clinical and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. The facilities’ core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances.
“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combined business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” commented Steve Klosk, President and CEO of Cambrex.
Shawn Cavanagh, COO of Cambrex commented, “This acquisition expands our manufacturing footprint with the addition of two state-of-the art, GMP compliant manufacturing facilities in North America, both with a strong reputation for quality and excellent track records with regulatory approvals from the US FDA, EMEA, DEA and Health Canada. We look forward to welcoming the 450-person workforce in joining our existing 1,200 experts across the United States and Europe and to continue to build long-term partnerships with our customers.”
10-K for the period ended December 31, 2017 captioned “Risk Factors,” or otherwise described in the Company’s filings with the SEC provide examples of such risks and uncertainties that may cause the Company’s actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, customer and product concent
Halozyme Therapeutics recently said it would focus on its Enhanze delivery technology after HALO-301 – its candidate pancreatic cancer drug – fell short in Phase III trials.
The San Diego biotech will close its oncology operations and reduce its headcount by approximately 55%, or approximately 160 positions. (Read Xconomy’s report here).
?
Image: iStock/lovelyday12
But the reorganization is not likely to have an impact on biopharma contract development and manufacturing organization (CDMO) Avid Bioservices, which counts Halozyme as its largest customer. Avid first entered into a manufacturing contract with the firm in 2004 and produces recombinant human hyaluronidase enzyme for both Halozyme and its partners
California’s Avid Bioservices now has two simultaneous expansion projects underway as the CDMO’s projections for customer demand sparked the launch this week of the second phase of building out its Myford facility.
Avid expects construction on the second phase, which will be known as its Myford South facility to take 18 to 24 months to complete at a cost of roughly $45 million to $55 million, it said in a press release.
The biotech, which focuses mostly on mammalian cell-culture drug development, estimates that the addition of Myford South could increase its annual revenue-generating capacity by $100 million.
advertisement
advertisement
“With the continued strong growth that we have experienced in both revenue and customer demand in recent months and quarters, we feel that Avid is in a strong position to kick off the second phase of our Myford facility expansion,” Nicholas Green, Avid CEO, said in a statement.
The first phase of Avid’s expansion, the northern side of the Myford site, launched in the fourth quarter of 2020 and is primarily concerned with adding a second downstream processing suite at the location. The company estimates the first phase will take approximately 12 to 15 months to complete at an estimated cost of approximately $15 million.
That phase could increase the Avid’s annual revenue-generating capacity by $50 million, and the two expansions together could bring the company’s total revenue capacity to $270 million, it said.
The expansions continue a banner February for Avid, which earlier this month partnered with Humangien to manufacture lenzilumab, a monoclonal antibody therapeutic designed to treat cytokine storm caused by Covid-19. The drug has finished a Phase III clinical trial, and Avid signed on to help with scaling it for possible commercialization.
And in December, the biotech closed its initial public offering of over 3.8 million stock shares at $9 per share, generating some $34.5 million in revenue.
I'm thinking within 2 years that somebody will take us out. M&A
2019
East Rutherford, NJ – August 7, 2019 – Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced today that it has signed a definitive agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately $2.4 billion, including Cambrex’s net debt. Under the terms of the merger agreement, Cambrex shareholders will receive $60.00 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price and a 37.3% premium to the 60-day volume weighted average closing price leading up to this announcement.
Cambrex has grown to become the premier contract development and manufacturing organization in the small molecule space over the last several years. The recent acquisitions of Halo Pharma in 2018 and Avista Pharma Solutions in 2019 added drug product manufacturing and a full range of early stage and analytical testing services to the company’s leading position in drug substance manufacturing, allowing Cambrex to broaden customer relationships over the full product lifecycle, from pre-clinical through commercial.
“We are excited to announce this transaction with Permira, a global private equity firm that has made significant investments in the pharma services space. This agreement is a strong endorsement of our strategy and represents significant value for our shareholders,” commented Steve Klosk, President and CEO of Cambrex. “Cambrex will continue to invest aggressively in our commitment to our global customer base, where we are constantly looking at ways to provide the broadest possible range of world class services.”
“We are very excited to back Cambrex in its next phase of growth,” said Henry Minello, Principal in the Global Healthcare Group of Permira. “Over many years, Cambrex has built a leading position with best-in-class capabilities and facilities, backed by an excellent reputation for quality and technical expertise. We look forward to partnering with Cambrex’s talented management and employees to support the growth of its integrated services offering.”
Completion of the transaction is subject to customary closing conditions, including receipt of approval by Cambrex’s shareholders and customary regulatory approvals. Closing is expected to occur during the fourth quarter of 2019.
The transaction will be financed through a combination of debt and equity financing.
Under the terms of the agreement, Cambrex may actively solicit acquisition proposals from third parties during a 45-day “go-shop” period starting from the date of the agreement (which period may be extended under certain circumstances for an additional 15 days), and subject to customary requirements included in the agreement, enter into or recommend a transaction with a person or group that makes a superior proposal. There can be no assurance that this process will result in a superior proposal. Cambrex does not intend to disclose developments during this process unless and until the Board makes a decision with respect to any superior proposal it may receive.
Morgan Stanley & Co. LLC is acting as exclusive financial advisor and Kirkland & Ellis, LLP is serving as legal advisor to Cambrex. RBC Capital Markets is acting as exclusive financial advisor and provided committed debt financing to the Permira funds and Skadden, Arps, Slate, Meagher & Flom, LLP is serving as legal advisor to the Permira funds.
SHARE THIS PAGE
DOWNLOADSDOWNLOAD PDF VERSION
Media contacts
Nina Suter
Head of Communications - Director+44 (0) 207 632 1000nina.suter@permira.com
Related News & Views
MORE NEWS & VIEWS
?
Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabil...
News | 18th November 2020
FIND OUT MORE
?
Cambrex Announces Management Changes and Board Appointments
News | 6th January 2020
FIND OUT MORE
?
Cambrex Announces Completion of Acquisition by the Permira Funds
News | 4th December 2019
FIND OUT MORE
Will probably never make it 100.
Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs).
Cambrex CorporationTypePrivateIndustryPharmaceuticalsFoundedNew Jersey (1981)HeadquartersEast Rutherford, NJ
Key people
Steven M. Klosk, CEO, President,Revenue? 534.7 million USD (2017)
Net income
? 57.2 million USD (2015)Total assets? 505.5 million USD (2015)Total equity? 310.8 million USD (2015)
Number of employees
2,100+Websitecambrex.com
Cambrex has cGMP manufacturing facilities in the US (Agawam, MA; Charles City, IA; Durham, NC; High Point, NC; Longmont, CO; Whippany, NJ), Canada (Mirabel, Québec) and Europe (Edinburgh, UK; Karlskoga, Sweden, Milan, Italy, and R&D centers in Tallinn, Estonia, Wiesbaden, Germany). The headquarters are located in East Rutherford, NJ.
In 2007, Cambrex divested their biologics business to Lonza to focus on small molecule APIs.[1]
It's everyday that some idiot comes on a message board making outrageous, knee slapping claims.
I certainly hope that I'm not that idiot. (Cost basis 3.51)
You're getting the extra short version.
HALO has continued to ramp sales on Enhanze which we provide for.
In 24 to 30 months we'll be back to capacity including the new facilities.
The new money has to go be for expansion beyond what's already on the table.
Keep your eye on everything and let's see how it unfolds.
Remember you're only seconds away from a sale.
I have a large position in CDMO. That I accumulated over the last 20+ years. When we sign the deal, I have to watch the stock. Any good news and CDMO is rolling upward.....
There's no reason HGEN to stay down at these levels. Everything has been positive and the overhang from the financing seems to be worked out of the stock.
I don't own any shares yet but right here it sure looks good. .
Trying to get in at 15.....
I had a chance to speak to Dan, and we're going to be working together to try to get this company current.
If this happens the stock will be up a great deal.
If any of you guys want to participate just send me a private message.
Finally a decent buy 41,900....
20.01